166 related articles for article (PubMed ID: 30181806)
1. Somatic genome alterations in relation to age in lung squamous cell carcinoma.
Meucci S; Keilholz U; Heim D; Klauschen F; Cacciatore S
Oncotarget; 2018 Aug; 9(63):32161-32172. PubMed ID: 30181806
[TBL] [Abstract][Full Text] [Related]
2. Somatic genome alterations in relation to age in lung adenocarcinoma.
Meucci S; Keilholz U; Heim D; Klauschen F; Cacciatore S
Int J Cancer; 2019 Oct; 145(8):2091-2099. PubMed ID: 30859574
[TBL] [Abstract][Full Text] [Related]
3. Mutational signatures in squamous cell carcinoma of the lung.
Osoegawa A; Takada K; Okamoto T; Sato S; Nagahashi M; Tagawa T; Tsuchida M; Oki E; Okuda S; Wakai T; Mori M
J Thorac Dis; 2021 Feb; 13(2):1075-1082. PubMed ID: 33717580
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Profiling of Genomic and Transcriptomic Differences between Risk Groups of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Zengin T; Önal-Süzek T
J Pers Med; 2021 Feb; 11(2):. PubMed ID: 33672117
[TBL] [Abstract][Full Text] [Related]
5. Unique genomic features and prognostic value of COSMIC mutational signature 4 in lung adenocarcinoma and lung squamous cell carcinoma.
Cai X; Chen Z; Deng M; Li Z; Wu Q; Wei J; Dai C; Wang G; Luo C
Ann Transl Med; 2020 Sep; 8(18):1176. PubMed ID: 33241025
[TBL] [Abstract][Full Text] [Related]
6. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates.
Meng F; Zhang L; Ren Y; Ma Q
J Cell Physiol; 2019 Jul; 234(7):10918-10925. PubMed ID: 30549039
[TBL] [Abstract][Full Text] [Related]
7. Whole-exome Sequencing in Penile Squamous Cell Carcinoma Uncovers Novel Prognostic Categorization and Drug Targets Similar to Head and Neck Squamous Cell Carcinoma.
Chahoud J; Gleber-Netto FO; McCormick BZ; Rao P; Lu X; Guo M; Morgan MB; Chu RA; Martinez-Ferrer M; Eterovic AK; Pickering CR; Pettaway CA
Clin Cancer Res; 2021 May; 27(9):2560-2570. PubMed ID: 33441293
[TBL] [Abstract][Full Text] [Related]
8. Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas.
Desrichard A; Kuo F; Chowell D; Lee KW; Riaz N; Wong RJ; Chan TA; Morris LGT
J Natl Cancer Inst; 2018 Dec; 110(12):1386-1392. PubMed ID: 29659925
[TBL] [Abstract][Full Text] [Related]
9. A prognostic 11-DNA methylation signature for lung squamous cell carcinoma.
Zhang J; Luo L; Dong J; Liu M; Zhai D; Huang D; Ling L; Jia X; Luo K; Zheng G
J Thorac Dis; 2020 May; 12(5):2569-2582. PubMed ID: 32642165
[TBL] [Abstract][Full Text] [Related]
10. Exome-wide analysis of bi-allelic alterations identifies a Lynch phenotype in The Cancer Genome Atlas.
Buckley AR; Ideker T; Carter H; Harismendy O; Schork NJ
Genome Med; 2018 Sep; 10(1):69. PubMed ID: 30217226
[TBL] [Abstract][Full Text] [Related]
11. Tumor mutation burden (TMB)-associated signature constructed to predict survival of lung squamous cell carcinoma patients.
Yan D; Chen Y
Sci Rep; 2021 Apr; 11(1):9020. PubMed ID: 33907270
[TBL] [Abstract][Full Text] [Related]
12. Specific Lung Squamous Cell Carcinoma Prognosis-Subtype Distinctions Based on DNA Methylation Patterns.
Huang G; Zhang J; Gong L; Liu D; Wang X; Chen Y; Guo S
Med Sci Monit; 2021 Mar; 27():e929524. PubMed ID: 33661858
[TBL] [Abstract][Full Text] [Related]
13. Integrative analysis of genomic alteration, immune cells infiltration and prognosis of lung squamous cell carcinoma (LUSC) to identify smoking-related biomarkers.
Li J; Li H; Zhang C; Zhang C; Wang H
Int Immunopharmacol; 2020 Dec; 89(Pt A):107053. PubMed ID: 33045568
[TBL] [Abstract][Full Text] [Related]
14. Two main mutational processes operate in the absence of DNA mismatch repair.
Németh E; Lovrics A; Gervai JZ; Seki M; Rospo G; Bardelli A; Szüts D
DNA Repair (Amst); 2020 May; 89():102827. PubMed ID: 32126497
[TBL] [Abstract][Full Text] [Related]
15. A Novel Prognosis Signature Based on Ferroptosis-Related Gene DNA Methylation Data for Lung Squamous Cell Carcinoma.
Wang X; Meng Y; Liu C; Yang H; Zhou S
J Oncol; 2022; 2022():9103259. PubMed ID: 36131791
[TBL] [Abstract][Full Text] [Related]
16. A glycolysis-based three-gene signature predicts survival in patients with lung squamous cell carcinoma.
Huang G; Zhang J; Gong L; Huang Y; Liu D
BMC Cancer; 2021 May; 21(1):626. PubMed ID: 34044809
[TBL] [Abstract][Full Text] [Related]
17. M7G-Related lncRNAs predict prognosis and regulate the immune microenvironment in lung squamous cell carcinoma.
Pan J; Huang Z; Lin H; Cheng W; Lai J; Li J
BMC Cancer; 2022 Nov; 22(1):1132. PubMed ID: 36333719
[TBL] [Abstract][Full Text] [Related]
18. Multiple mutations of lung squamous cell carcinoma shared common mechanisms.
Li Q; Hou J; Hu Z; Gu B; Shi Y
Oncotarget; 2016 Nov; 7(48):79629-79636. PubMed ID: 27835590
[TBL] [Abstract][Full Text] [Related]
19. Deciphering a cell death-associated signature for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma.
Mao G; Yang D; Liu B; Zhang Y; Ma S; Dai S; Wang G; Tang W; Lu H; Cai S; Zhu J; Yang H
Respir Res; 2023 Jul; 24(1):176. PubMed ID: 37415224
[TBL] [Abstract][Full Text] [Related]
20. Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy.
Xu Y; Li H; Huang Z; Chen K; Yu X; Sheng J; Zhang HH; Fan Y
Transl Lung Cancer Res; 2020 Dec; 9(6):2367-2379. PubMed ID: 33489799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
